Table 1.
Demography and Clinical Characteristics of ESRD patients on pretransplant pre-emptive, HD or PD who received KT from DCD
| Characteristics | PKT group (n = 5) |
HD group (n = 104) |
PD group (n = 98) |
p-value |
|---|---|---|---|---|
| Age(years) | 36.2 ± 10.1 | 42.4 ± 9.7 | 39.5 ± 11.6 | 0.053 |
| Male, n (%) | 4(80.0) | 65(62.5) | 56(57.1) | 0.437 |
| BMI (kg/m2) | 22.1(20.2,26.1) | 21.2(18.9,23.6) | 21.5(19.9,23.8) | 0.470 |
| Blood group (A:B:AB:O) | 2:2:0:1 | 27:26:13:38 | 27:29:8:34 | 0.706 |
| Duration on dialysis (months) | 0(0,0) | 15.5(6.0,36.0) | 24.0(6.0,36.0) | 0.583 |
| Hospital stay (days) | 17.0(12.5,19.5) | 20.0(15.0,26.0) | 18.5(15.0,29.0) | 0.337 |
| Follow-up time (months) | 19.0(10.5,35.0) | 12.5(3.0,22.0) | 12.0(6.0,20.0) | 0.961 |
| Preoperative medical condition, n (%) | ||||
| Diabetes mellitus | 0(0) | 13(12.5) | 6(6.1) | 0.121 |
| Cardiovascular disease | 0(0) | 5(4.8) | 2(2.0) | 0.490 |
| Hypertension | 5(100) | 91(87.5) | 90(91.8) | 0.313 |
| Antihypertensive agents, n (%) | 5(100) | 76(73.1) | 75(76.5) | 0.572 |
| HBV (+) | 0(0) | 9(8.7) | 8(8.2) | 0.900 |
| Cause of end-stage renal disease, n (%) | 0.188 | |||
| Glomerulonephritis | 4(80) | 68(64.8) | 64(66.0) | |
| Diabetes | 0(0) | 5(4.8) | 1(1.0) | |
| Hypertensive nephrosclerosis | 0(0) | 2(1.9) | 1(1.0) | |
| Polycystic kidney disease | 1(20) | 6(5.7) | 1(1.0) | |
| Chronic pyelonephritis | 0(0) | 1(1.0) | 2(2.1) | |
| Others | 0(0) | 2(1.9) | 6(6.2) | |
| Unknown | 0(0) | 21(20.0) | 22(22.7) | |
| Pretransplant urinary volume (ml/24 h) | 2000(1750,2000) | 200(100,500) | 500(100,1000) | 0.073 |
| Anuric patients (%) | 0(0) | 19(18.3) | 18(18.4) | 0.986 |
| Immunosuppresion therapy, n (%) | 0.310 | |||
| St + FK + MMF | 5(100) | 97(93.3) | 95(96.9) | |
| St + CyA | 0(0) | 2(1.9) | 0(0) | |
| St + CyA + MMF | 0(0) | 5(4.8) | 3(3.1) | |
P-value, between hemodialysis and peritoneal dialysis group
ERSD end stage renal disease, HD hemodialysis, PD peritoneal dialysis, PKT pre-emptive kidney transplantation, KT kidney transplantation, DCD donor after cardiac death, BMI body mass index, HBV hepatitis B virus, St steroids, FK tacrolimus, MMF mofetil mycofenolate, CyA cyclosporine A